• DOI:10.1007/BF03189744
• Corpus ID: 2196891

Metabolism of the anti-depressant lortalamine

@article{Elsom2010MetabolismOT,
  title={Metabolism of the anti-depressant lortalamine},
  author={L. F. Elsom and S. R. Biggs and Leslie F Chasseaud and David R. Hawkins and J. R. Pulsford and Austin Darragh},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2010},
  volume={10},
  pages={209-215}
}

• L. F. Elsom, S. Biggs, +3 authors A. Darragh
• Published 1 July 1985
• Biology
• European Journal of Drug Metabolism and Pharmacokinetics

SummaryHumans excreted an oral dose of 5 mg of the anti-depressant lortalamine (radiolabelled with carbon-14) mainly in the urine (98% during 5 days).Plasmal 4C concentrations were highest (about 44 ng equiv./ml) between 1.5–3 h when the corresponding concentrations of unchanged drug were about 17 ng/ml. Unchanged drug concentrations appeared to decline with a half-life of about 5 h. Concentrations of14C then declined rapidly and were below the limits of detection (12 ng equiv./ml) at 24–36 h.Measurement of whole-blood14C concentrations showed that there was some u p t a k e into the blood cells (about 65% of the peak plasma14C level).Radioactivity in the urine was mainly associated with unchanged drug and three metabolites. The major metabolite (about 50% urinary14C) was identified by mass spectrometry as the N-demethylated compound and another metabolite as a keto derivative of lortalamine where oxidation had occurred in the piperidine ring.